Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow [Yahoo! Finance]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Yahoo! Finance
In the year-ago quarter, the company reported earnings of 69 cents per ADS. Revenues grew 12% year over year to $850 million, surpassing the Zacks Consensus Estimate of $825 million. The year-over-year improvement was primarily driven by growth in global generics revenues in North America as well as Emerging Markets. Shares of the company have gained 2.5% year to date compared with the industry's 5% growth. Image Source: Zacks Investment Research Quarter in Detail Dr. Reddy's reports revenues under three segments: Global Generics, Pharmaceutical Services & Active Ingredients (PSAI) and Others. Global Generics revenues were INR 61.2 billion, up 13% year over year, in the fiscal fourth quarter. The increase was primarily driven by new product launches and increased volumes of the company's existing core products, partially offset by price erosion in certain markets. During the reported quarter, Dr. Reddy's launched five new products in the North America region, of which fo
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- US Generic Drug Industry Research 2024-2032: $124 Billion Market Analysis by Segment, Therapy Area, Drug Delivery, & Distribution Channel [Yahoo! Finance]Yahoo! Finance
- Non-Steroidal Anti-Inflammatory Drugs Market Size to Worth USD 33.55 Bn by 2032 [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- India's Alembic Pharma posts higher Q4 profit on strong N.America sales [Reuters]Reuters
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
RDY
Earnings
- 5/8/24 - Beat
RDY
Sec Filings
- 5/17/24 - Form 6-K
- 5/15/24 - Form 6-K
- 5/13/24 - Form 6-K
- RDY's page on the SEC website